BAX Quote, Financials, Valuation and Earnings

Becton, Dickinson & Co. has a net margin of -34.8% compared to Baxter International, Inc.'s net margin of 7.27%. Baxter International, Inc.'s return on equity of -12.97% beat Becton, Dickinson & Co.'s return on equity of 6.94%.

Baxter International, Inc. has a consensus price target of $21.63, signalling upside risk potential of 0.25%. On the other hand Becton, Dickinson & Co. has an analysts' consensus of $195.38 which suggests that it could grow by 5.39%. Given that Becton, Dickinson & Co. has higher upside potential than Baxter International, Inc., analysts believe Becton, Dickinson & Co. is more attractive than Baxter International, Inc..

Baxter International, Inc. has a beta of 0.593, which suggesting that the stock is 40.747% less volatile than S&P 500. In comparison Becton, Dickinson & Co. has a beta of 0.248, suggesting its less volatile than the S&P 500 by 75.233%.

Baxter International, Inc. has a quarterly dividend of $0.01 per share corresponding to a yield of 2.41%. Becton, Dickinson & Co. offers a yield of 1.77% to investors and pays a quarterly dividend of $0.83 per share. Baxter International, Inc. pays 180.98% of its earnings as a dividend. Becton, Dickinson & Co. pays out 71.53% of its earnings as a dividend. Becton, Dickinson & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Baxter International, Inc.'s is not.

Baxter International, Inc. quarterly revenues are $3B, which are smaller than Becton, Dickinson & Co. quarterly revenues of $5.3B. Baxter International, Inc.'s net income of -$1B is lower than Becton, Dickinson & Co.'s net income of $382M. Notably, Baxter International, Inc.'s price-to-earnings ratio is 167.20x while Becton, Dickinson & Co.'s PE ratio is 30.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International, Inc. is 0.99x versus 2.43x for Becton, Dickinson & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of -34.8% compared to Baxter International, Inc.'s net margin of 12.68%. Baxter International, Inc.'s return on equity of -12.97% beat Boston Scientific Corp.'s return on equity of 12.55%.

Baxter International, Inc. has a consensus price target of $21.63, signalling upside risk potential of 0.25%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.75 which suggests that it could grow by 40.45%. Given that Boston Scientific Corp. has higher upside potential than Baxter International, Inc., analysts believe Boston Scientific Corp. is more attractive than Baxter International, Inc..

Baxter International, Inc. has a beta of 0.593, which suggesting that the stock is 40.747% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.

Baxter International, Inc. has a quarterly dividend of $0.01 per share corresponding to a yield of 2.41%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Baxter International, Inc. pays 180.98% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Baxter International, Inc. quarterly revenues are $3B, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Baxter International, Inc.'s net income of -$1B is lower than Boston Scientific Corp.'s net income of $670M. Notably, Baxter International, Inc.'s price-to-earnings ratio is 167.20x while Boston Scientific Corp.'s PE ratio is 38.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International, Inc. is 0.99x versus 5.55x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

ResMed, Inc. has a net margin of -34.8% compared to Baxter International, Inc.'s net margin of 27.59%. Baxter International, Inc.'s return on equity of -12.97% beat ResMed, Inc.'s return on equity of 25.44%.

Baxter International, Inc. has a consensus price target of $21.63, signalling upside risk potential of 0.25%. On the other hand ResMed, Inc. has an analysts' consensus of $297.47 which suggests that it could grow by 14.8%. Given that ResMed, Inc. has higher upside potential than Baxter International, Inc., analysts believe ResMed, Inc. is more attractive than Baxter International, Inc..

Baxter International, Inc. has a beta of 0.593, which suggesting that the stock is 40.747% less volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.869, suggesting its less volatile than the S&P 500 by 13.099%.

Baxter International, Inc. has a quarterly dividend of $0.01 per share corresponding to a yield of 2.41%. ResMed, Inc. offers a yield of 0.9% to investors and pays a quarterly dividend of $0.60 per share. Baxter International, Inc. pays 180.98% of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Baxter International, Inc.'s is not.

Baxter International, Inc. quarterly revenues are $3B, which are larger than ResMed, Inc. quarterly revenues of $1.4B. Baxter International, Inc.'s net income of -$1B is lower than ResMed, Inc.'s net income of $392.6M. Notably, Baxter International, Inc.'s price-to-earnings ratio is 167.20x while ResMed, Inc.'s PE ratio is 25.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International, Inc. is 0.99x versus 7.05x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of -34.8% compared to Baxter International, Inc.'s net margin of 11.84%. Baxter International, Inc.'s return on equity of -12.97% beat Stryker Corp.'s return on equity of 15.17%.

Baxter International, Inc. has a consensus price target of $21.63, signalling upside risk potential of 0.25%. On the other hand Stryker Corp. has an analysts' consensus of $424.40 which suggests that it could grow by 11.62%. Given that Stryker Corp. has higher upside potential than Baxter International, Inc., analysts believe Stryker Corp. is more attractive than Baxter International, Inc..

Baxter International, Inc. has a beta of 0.593, which suggesting that the stock is 40.747% less volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.873, suggesting its less volatile than the S&P 500 by 12.679%.

Baxter International, Inc. has a quarterly dividend of $0.01 per share corresponding to a yield of 2.41%. Stryker Corp. offers a yield of 0.89% to investors and pays a quarterly dividend of $0.88 per share. Baxter International, Inc. pays 180.98% of its earnings as a dividend. Stryker Corp. pays out 40.48% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Baxter International, Inc.'s is not.

Baxter International, Inc. quarterly revenues are $3B, which are smaller than Stryker Corp. quarterly revenues of $7.2B. Baxter International, Inc.'s net income of -$1B is lower than Stryker Corp.'s net income of $849M. Notably, Baxter International, Inc.'s price-to-earnings ratio is 167.20x while Stryker Corp.'s PE ratio is 45.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Baxter International, Inc. is 0.99x versus 5.85x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.